$PBHC

Pathfinder Bancorp, Inc. (NASDAQ:PBHC) Sees Large Increase in Short Interest

Pathfinder Bancorp (NASDAQ:PBHC) experienced a significant 30.5% increase in short interest as of April 15th, totaling 8,863 shares. This represents approximately 0.2% of its shares and a short-interest ratio of 2.9 days. The company recently reported $0.38 EPS for the quarter with negative return on equity and net margin, and declared a $0.10 quarterly dividend.

Original reporting
MarketBeat · MarketBeat
Published Apr 30, 2026, 1:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 30, 2026, 7:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pathfinder Bancorp, Inc. (NASDAQ:PBHC) Sees Large Increase in Short Interest — source image
Decision brief

The 30-second read

$PBHCBearishMed
01

Why it matters

The rise in short interest suggests traders expect further declines, possibly due to sector headwinds or company-specific issues.

02

Market read

The news is highly relevant for traders with exposure or interest in regional banking stocks, indicating potential short-term volatility.

03

What to watch

Potential for company turnaround if management implements strategic changes; macroeconomic factors favoring regional banks.

Timing: Immediate to short-term

Background

Pathfinder Bancorp reported weak quarterly earnings with a loss and declining margins, prompting increased short selling activity.

Company-level read

Ticker impact

$PBHCBearishMedium confidence
Context

High relevance due to significant increase in short interest and recent earnings report.

Expected impact

Potential short-term decline or increased volatility; long-term impact uncertain without further fundamental improvements.

Evidence & confidence

The surge in short interest combined with weak earnings suggests increased downside risk. Nonetheless, the dividend and current valuation may provide support, making the outlook uncertain.

Market effects

Potential negative sentiment affecting regional banking and financial services sectors.

Limited impact outside regional banking markets; primarily affecting local investor sentiment.

Negligible; company-specific news with minimal global influence.

Counterpoint

The increase in short interest may be a temporary overreaction; the dividend and modest valuation could present a buying opportunity for contrarian investors.

Key entities

  • Pathfinder Bancorp, Inc.

    A regional bank operating in local markets with recent earnings challenges.

Related articles

$PBHCMed

Prosperity Bancshares, Inc. Q2 2026 Earnings Call Summary

Strategic Integration and Performance Drivers Management successfully closed the Stellar Bancorp merger on July 1, 2026, adding 52 banking offices and significantly expanding the Houston and East Texas footprint. Core net income growth of 20.4% year-over-year was driven by the repricing of assets and the successful inclusion of American Bank and Texas Partners Bank results.

$PBHCMed

Pathfinder Bancorp, Inc. (PBHC): Results of Operations and Financial Condition

Pathfinder Bancorp, Inc. (PBHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Investor/Media Contacts James A. Dowd, President, CEO Justin K. Bigham, Executive Vice President, CFO Telephone: (315) 343-0057 Pathfinder Bancorp, Inc. Announces Financial Results for the Second Quarter of 2026 Pathfinder grew earnings to $0.42 per share in the second quarter of

$NXEMed

Is BHP Group (BHP) the Missing Piece in NexGen Energy (NXE)’s $1 Billion Financing Plan?

NexGen Energy (NXE) is in talks with BHP Group (BHP) for a potential equity stake and financing for its Rook I uranium project. NexGen aims to raise $1 billion over nine months. BHP reported strong financials, with $33 billion in EBITDA and $9.8 billion in free cash flow. NexGen has no revenue but holds $970.25 million in cash. Investors should watch for a formal partnership between the two.

$AZNMed

13 clinical candidates revealed in Chicago

At the American Chemical Society Fall 2026 meeting, 13 new drug candidates were unveiled by various companies, targeting diseases like cancer, lupus, and acne. Presenters included Quanta Therapeutics, AstraZeneca, Novartis, and Pfizer, among others, discussing their drug discovery strategies and clinical trials.